177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment

Majid Assadi; Hojjat Ahmadzadehfar

doi:10.4103/wjnm.WJNM_112_18

World Journal of Nuclear Medicine, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(04): 406-408
DOI: 10.4103/wjnm.WJNM_112_18

Case Report

¹⁷⁷Lu-DOTATATE and ¹⁷⁷Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment

Authors

Majid Assadi

The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran
Hojjat Ahmadzadehfar

¹Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

Abstract

Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial side effects and a high cost. Somatostatin receptor-based therapies have shown promising findings in advanced RrDTC. Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. This study presents a case of RrDTC who was treated with ¹⁷⁷Lu-DOTATATE and ¹⁷⁷Lu-PSMA, presumably as a first report in this regard.

Keywords

¹⁷⁷Lu - DOTATATE - prostate-specific membrane antigen - radioiodine-refractory differentiated thyroid cancer

Volltext

Referenzen

References
1 Salavati A, Puranik A, Kulkarni HR, Budiawan H, Baum RP. Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues. Semin Nucl Med 2016;46:215-24.
2 Roll W, Riemann B, Schäfers M, Stegger L, Vrachimis A 177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid cancer: A Single center experience. Clin Nucl Med 2018;43:e346-51.
3 Taywade SK, Damle NA, Bal C. PSMA expression in papillary thyroid carcinoma: Opening a new horizon in management of thyroid cancer? Clin Nucl Med 2016;41:e263-5.
4 Sager S, Vatankulu B, Uslu L, Sönmezoglu K. Incidental detection of follicular thyroid carcinoma in 68Ga-PSMA PET/CT imaging. J Nucl Med Technol 2016;44:199-200.
5 Budiawan H, Salavati A, Kulkarni HR, Baum RP. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using(90) Yttrium and (177)Lutetium labeled somatostatin analogs: Toxicity, response and survival analysis. Am J Nucl Med Mol Imaging 2013;4:39-52.
6 Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: A new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid 2014;24:715-26.